Chemistry
Sargramostim is a recombinant version of GM-CSF, which is a glycoprotein made of 127 amino acids; sargramostim is mixture of three versions of GM-CSF that have molecular weights of 19,500, 16,800 and 15,500 Daltons. It is manufactured in yeast. History
The sequence of human GM-CSF was first identified in 1985 and soon three recominbant human GM-CSFs were produced, one in bacteria, one in mammalian cells, and one in yeast; Immunex developed GM-CSF manufactured in yeast into Leukine. Clinical trials of sargramostim were initiated in 1987; in that same year it was administered to six people as part of a compassionate-use protocol for the victims of cesium irradiation from the Goiânia accident.It was approved by the FDA in March 1991 under the trade name Leukine for acceleration of white blood cell recovery following autologous bone marrow transplantation in patients with non-Hodgkins lymphoma, acute lymphocytic leukemia, or Hodgkins disease. In November 1996, the FDA also approved sargramostim for treatment of fungal infections and replenishment of  white blood cells following chemotherapy. A liquid formulation was approved in 1995. Immunex was acquired by Amgen in 2002. As part of the acquisition,  Leukine was spun off to Berlex, which became Bayer HealthCare in 2007.In January 2008, Bayer informed healthcare professionals of the market withdrawal of the current liquid formulation of sargramostim.
Diagnosis involves testing and evaluation during which it is determined if the scores/performance are "substantially below" developmental expectations and if they "significantly" interfere with academic achievement, social interactions, and daily living. This assessment may also determine if the characteristic is deviant or delayed. Therefore, it may be possible for an individual to have communication challenges but not meet the criteria of being "substantially below" criteria of the DSM IV-TR. The DSM diagnoses do not comprise a complete list of all communication disorders, for example, auditory processing disorder is not classified under the DSM or ICD-10. The following diagnoses are included as communication disorders:

Expressive language disorder – characterized by difficulty expressing oneself beyond simple sentences and a limited vocabulary. Individuals can better understand than use language; they may have a lot to say, but have more difficulty organizing and retrieving the words than expected for their developmental stage. Mixed receptive-expressive language disorder – problems comprehending the commands of others. Stuttering – a speech disorder characterized by a break in fluency, where sounds, syllables, or words may be repeated or prolonged. Phonological disorder – a speech sound disorder characterized by problems in making patterns of sound errors (e.g., "dat" for "that"). Communication disorder NOS (not otherwise specified) – the DSM-IV diagnosis in which disorders that do not meet the specific criteria for the disorder listed above may be classified. DSM-5
The DSM-5 diagnoses for communication disorders completely rework the ones stated above.